Milestone Pharmaceuticals Inc.
MIST
$1.07
-$0.06-4.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 155.56% | 32.75% | 57.97% | 39.55% | 29.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 108.99% | 16.46% | 52.28% | 23.01% | 29.69% |
| Operating Income | -104.53% | -15.30% | -39.76% | -23.01% | -29.69% |
| Income Before Tax | -120.68% | -25.55% | -40.82% | -26.31% | -38.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -120.68% | -25.55% | -40.82% | -26.31% | -38.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -120.68% | -25.55% | -40.82% | -26.31% | -38.48% |
| EBIT | -104.53% | -15.30% | -39.76% | -23.01% | -29.69% |
| EBITDA | -104.53% | -15.18% | -39.77% | -23.07% | -29.75% |
| EPS Basic | -5.63% | 36.11% | 11.96% | 13.32% | -38.02% |
| Normalized Basic EPS | -5.57% | 36.16% | 12.01% | 13.36% | -38.12% |
| EPS Diluted | -5.63% | 36.11% | 11.96% | 13.32% | -38.02% |
| Normalized Diluted EPS | -5.57% | 36.16% | 12.01% | 13.36% | -38.12% |
| Average Basic Shares Outstanding | 108.94% | 96.55% | 60.00% | 45.78% | 0.32% |
| Average Diluted Shares Outstanding | 108.94% | 96.55% | 60.00% | 45.78% | 0.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |